Scinai Immunotherapeutics (SCNI) Other financing activities (2018 - 2024)

Scinai Immunotherapeutics has disclosed Other financing activities across 7 years of filings, most recently posting $145000.0 for Q3 2024.

• Other financing activities for Q3 2024 came in at $145000.0, down 38.03% year-over-year; the trailing twelve-month figure through Sep 2024 was $661000.0 (down 39.02% YoY), and the FY2023 annual result was $869000.0, down 45.76% from the prior year.
• Other financing activities came in at $145000.0 for Q3 2024 at Scinai Immunotherapeutics, up from $142000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $4.6 million in Q3 2020 to a low of $341.0 in Q2 2022.
• The 5-year median for Other financing activities is $366000.0 (2022), against an average of $1.0 million.
• Across the five-year window, Other financing activities slumped 99.99% in 2022 and jumped 58551.03% in 2023, its largest moves.
• Scinai Immunotherapeutics' Other financing activities stood at $1.3 million in 2020, then tumbled by 45.83% to $727000.0 in 2021, then sank by 45.25% to $398000.0 in 2022, then plunged by 54.02% to $183000.0 in 2023, then decreased by 20.77% to $145000.0 in 2024.
• The last three Other financing activities figures came in at $145000.0 (Q3 2024), $142000.0 (Q2 2024), and $191000.0 (Q1 2024), per Business Quant data.